Antiplatelet and PPI Use in Kidney Disease Patients
Author Information
Author(s): Michael Che, Sumaiya Ahmed, Ryan Chan, Ayub Akbari, Deborah Zimmerman
Primary Institution: University of Toronto
Hypothesis
Are patients with end-stage kidney disease appropriately prescribed dual antiplatelet therapy and proton pump inhibitors?
Conclusion
The study found that prescribing patterns of DAPT and PPI are unlikely to significantly contribute to the increased risk of gastrointestinal bleeding in hemodialysis patients.
Supporting Evidence
- 44 patients were on antiplatelet therapy, with only 4 on dual antiplatelet therapy.
- 39 patients were prescribed proton pump inhibitors, but only 14% had an absolute indication for therapy.
- 3% of patients had a current indication for dual antiplatelet therapy.
Takeaway
This study looked at whether patients with severe kidney disease are getting the right medications to prevent stomach bleeding. It found that most are not getting the wrong medications.
Methodology
A retrospective chart review was conducted to assess medication prescriptions and indications for patients with end-stage kidney disease.
Potential Biases
Medication lists were obtained from electronic medical records and not verified with patient interviews.
Limitations
The study was conducted at a single center, which may limit the generalizability of the results.
Participant Demographics
{"average_age":67.1,"gender_distribution":{"male":60.2,"female":39.8},"duration_of_ESKD":{"median":2.4,"IQR":"1.7-3.8"}}
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website